While other MAs have evaluated the efficacy and/or safety of anti-PD-L1-containing strategies [7,8,9,29,30,31,32,33,34,35,36,37,38], to date this is the first safety MA to include studies evaluating first-line single immunotherapy agents in NSCLC patients with a PD-L1 positive expression enriched design. This evidence concerns the gene CD274 and non-small cell lung carcinoma.